This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
2/19/2025
Martin
Host/Interviewer
Welcome to today's live broadcast from Modus Therapeutics, where we have with us the company's CEO, John Öd, to comment on the book release communiqué that the company presented here this morning, on January 20, 2025. And as usual, you can, as a follower of this live broadcast, ask questions to John directly in the chat. We have actually already received some questions, but that's just asking questions, so let's make sure that John can answer them as soon as possible. But then I say welcome to John, first and foremost.
John Öd
CEO
Thank you, Martin.
Martin
Host/Interviewer
The end of the book came out here this morning. You describe it as a revolving year for Modus, characterized by groundbreaking clinical progress and an enhanced pipeline. I'm just thinking about how you see the ongoing year and the position of the company before 2025.
You're reading a preview of the MODTX.ST Q4 2024 earnings call.
Free account.
Disclaimer